Browse the corpus

REFERENCES Acharya M, Bernard A, Gonzalez M, et al, “Open-Label, Phase I, Pharmacokinetic Studies of Abiraterone Acetate in Healthy Men,” Cancer Chemother Pharmacol , 2012, 69(6):1583-90. [PubMed 22526411 ] Attard G, Reid AH, A’Hern R, et al, “Selective Inhibition of CYP17 With Abiraterone Acetate is Highly Active in the Treatment of Castration-Resistant Prostate Cancer,” J Clin Oncol , 2009, 27(23):3742-8. [PubMed 19470933 ] Danila DC, Morris MJ, de Bono JS, et al, “Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer,” J Clin Oncol , 2010, 28(9):1496-501. [PubMed 20159814 ] de Bono JS, Logothetis CJ, Molina A, et al, “Abiraterone and Increased Survival in Metastatic Prostate Cancer,” New Engl J Med , 2011, 364(21):1995-2005. Fizazi K, Scher HI, Molina A, et al, “Abiraterone Acetate for Treatment of Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Analysis of the COU-AA-301 Randomised, Double-Blind, Placebo-Controlled Phase 3 Study,” Lancet Oncol , 2012, 13(10):983-92. [PubMed 22995653 ] National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Reid AH, Attard G, Danila DC, et al, “Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate,” J Clin Oncol , 2010, 28(9):1489-95. [PubMed 20159823 ] Ryan CJ, Shah S, Efstathiou E, et al, “Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant With Serologic Response,” Clin Cancer Res , 2011, 17(14):4854-61. [PubMed 21632851 ] Ryan CJ, Smith MR, de Bono JS, et al, “Interim Analysis (IA) Results of COU-AA-302, a Randomized, Phase III Study of Abiraterone Acetate (AA) in Chemotherapy-Naive Patients (Pts) With Metastatic Castration-Resistant Prostate Cancer (mCRPC),” J Clin Oncol , 2012, 30(18s): LBA4518 [abstract LBA4518 from 2012 ASCO Annual Meeting].

Ryan CJ, Smith MR, de Bono JS, et al, “Interim Analysis (IA) Results of COU-AA-302, a Randomized, Phase III Study of Abiraterone Acetate (AA) in Chemotherapy-Naive Patients (Pts) With Metastatic Castration-Resistant Prostate Cancer (mCRPC),” J Clin Oncol , 2012, 30(18s): LBA4518 [abstract LBA4518 from 2012 ASCO Annual Meeting]. Ryan CJ, Smith MR, Fong L, et al, “Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy,” J Clin Oncol, 2010, 28(9):1481-8. [PubMed 20159824 ] Tolcher AW, Chi KN, Shore ND, et al, “Effect of Abiraterone Acetate Plus Prednisone on the QT Interval In Patients With Metastatic Castration-Resistant Prostate Cancer,” Cancer Chemother Pharmacol , 2012, 70(2):305-13. [PubMed 22752297 ] Topic 16083 Version 38.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.4 - C21.36 Licensed to: Southeast Alabama Med Ctr | Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]